^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
DS-2087b
i
Other names: DS-2087b, DS 2087b
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Daiichi Sankyo
Drug class:
HER2 exon 20 mutation inhibitor
Related drugs:
almost4years
[VIRTUAL] Preclinical evaluation of DS-2087b, a novel and selective inhibitor of EGFR/HER2 exon 20 insertions (ESMO 2020)
Methods We evaluated the inhibitory effects of DS-2087b and poziotinib, an investigational tyrosine kinase inhibitor against Ba/F3 cells harboring WT EGFR and against EGFR/HER2 ex20ins mutations, including EGFR V769_D770 insertion ASV (EGFR ins.ASV); EGFR D770_N771 insertion SVD (EGFR ins.SVD); and HER2 A775_G776 insertion YVMA (HER2 ins.YVMA). Legal entity responsible for the study: Yuki Abe. Funding: Daiichi Sankyo Company, Limited.
Preclinical
|
EGFR (Epidermal growth factor receptor)
|
HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 A775
|
Pozenveo (poziotinib) • DS-2087b
Share via
